Listen To Story Above
In a rare medical case, researchers at the University of Toronto have documented an unusual occurrence of gigantomastia linked to the Pfizer COVID-19 vaccine. The case involves a 19-year-old woman who experienced dramatic breast enlargement shortly after vaccination.
The patient, who had no previous health issues, noticed rapid breast growth within a week of receiving her initial Pfizer vaccine dose in September 2022. The situation intensified after her second dose, with her breast size expanding from a B cup to a triple G over a six-month period. This peculiar case has gained attention on social media platforms, where it has been informally termed the “Pfizer Boob Job.”
The condition, known as pseudoangiomatous stromal hyperplasia (PASH)–associated gigantomastia is a out of control growth of cells which typically causes benign lumps, but which can actually occur anywhere there is fatty tissue. It is a known, but rare side effect of the vaccine. pic.twitter.com/ck9zPyx85U
— Dissident Media (@DissidentMedia) January 7, 2025
Medical professionals conducted thorough examinations but found no hormonal irregularities or other underlying causes. The diagnosis pointed to pseudoangiomatous stromal hyperplasia (PASH), an uncommon condition characterized by unexplained fibrous tissue growth in the breasts. The connection between PASH and vaccines had not been previously reported in medical literature.
According to the medical journal:
This case presents a healthy young woman with rapid bilateral breast enlargement 1 week following Pfizer COVID-19 vaccine administration. After ruling out other potential causes, she underwent bilateral reduction mammoplasty, with histology revealing dense terminal duct lobular units interspersed with PASH.
The patient’s belief in the vaccine’s role in her condition was met with skepticism by primary care physicians, leading to diminished confidence in medical professionals. After consulting multiple specialists and trying various medications without success, surgical intervention became necessary.
A 19-year-old’s breast size grew to a 7th size post COVID-19 vaxx.
Scientists documented a rare case of gigantomastia. After 1st Pfizer dose, girl experienced tingling in her chest & noticed rapid growth. 2nd dose accelerated the process. No hormonal imbalances detected. pic.twitter.com/3wMtQjlOhH
— Alan Knitowski ∞/21M (@alanknit) January 4, 2025
PASH-related gigantomastia is extremely uncommon, with less than 20 cases documented worldwide. Current classification systems for gigantomastia don’t include PASH as a potential cause and lack specific details about breast growth progression and tissue characteristics. Including these elements could enhance treatment decisions and patient care.
The patient ultimately underwent bilateral reduction mammoplasty, which was complicated by excessive bleeding during surgery, requiring blood transfusions. Surgical specimens confirmed the PASH diagnosis. The medical community acknowledges the need for additional research to understand PASH’s origins, improve gigantomastia classification systems, and investigate possible connections between the Pfizer vaccine, gigantomastia, and PASH.
